Ann: Immutep achieves Fast Track designation for Efti from US FDA, page-50

Seems timely to revisit FT in light of the recent mind blowing results.

I Just googled up Fast Track(FT) designation. Average = 6.1 years from start of trial to FDA approval for trials that have received FT designation. Tacti 2 started in May 2018, so we are half way there on av. Tacti2/3 ph 2 due to complete in May 2023. Given the relationship with Keytruda I think we will see FDA approval as quickly as possible after the completion of the trial(assuming all goes well) . So bang on the average or a bit under for us. So pencil in approval within three years.

In addition, aprox two thirds of FDA approved drugs receive FT designation. The odds are in our favor.

Given that Immutep has turned into a news fountain, three years is going to fly by. And when we approach completion of the Tacti 3 trial the suspense and anticipation will be huge. I hope we get lots of updates over the journey.

Its a great time to get set and buckle up.


Just my opinion only.